In particular, the DSS-TAS active component shared only three genes with both the GE (HOXA1, GPRC5A and LYZ) and CN (ABL1, ABL2 and CTNNB1) and none with the mutational profiles; although this surprisingly small overlap may be attributed in part to the rather sparse mutation panel, it also demonstrates that the functional drug/target profiling provides added value to the genomics-only-based analyses and that the targets deemed functionally critical by the addiction scoring are not necessarily overlapping with those detected by genomic analyses of the same cancer cells. The gene discussed is GPRC5A; the disease is cancer.